The Office of Technology Commercialization (OTC) at Nationwide Children's Hospital and its expert team facilitate the transfer of innovative technologies and research ranging from new therapeutics — including the recently approved, first-of-their-kind gene therapies Zolgensma and ELEVIDYS, FDA-approved treatments for Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD) — to biomarkers, diagnostic tools and clinical tools — such as the Comfort Collar, designed to prevent pressure wounds around tracheostomy tubes — to outside partners to benefit patients, the local community and the general public. As a result, Nationwide Children’s Hospital has earned its reputation as an institution with a remarkable track record of moving Read more